Sabrina Serani

IMvigor011 showed significant improvement in survival outcomes with adjuvant atezolizumab in ctDNA-positive MIBC.

The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene fusion.

Most patients with lower-risk myelofibrosis, over a 4-year period, experienced disease progression, as demonstrated by the prospective MOST study.

Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.

Pembrolizumab plus chemotherapy did not improve disease-free survival in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3 KEYNOTE-B21 study.

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.

Patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with nadofaragene firadenovec experienced lasting responses to the therapy for up to 3 years.

The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

The American Society of Clinical Oncology updated its vaccine guidelines for patients with cancer — a population that may have a heightened infection risk.

Based on results from a post hoc analysis, researchers found that lurbinectedin was more effective and less toxic than topotecan for the treatment of small cell lung cancer.

Detecting minimal residual disease with ctDNA in patients with stage II/III colorectal cancer may strongly predict disease recurrence and the potential benefit from adjuvant chemotherapy.